10-Q: Pono Capital Two, Inc. Reports Net Loss in Second Quarter Amidst Business Combination Efforts

Pono Capital Two, Inc. reported a net loss for the second quarter of 2024, while continuing efforts to finalize its business combination with SBC Medical Group Holdings.

Summary

• Pono Capital Two, Inc., a blank check company, reported a net loss of $308,266 for the three months ended June 30, 2024, and a net loss of $600,812 for the six months ended June 30, 2024.
• The company's operating and formation costs were $460,648 for the quarter and $923,287 for the six-month period.
• Interest and dividend income from investments held in the Trust Account was $233,962 for the quarter and $491,297 for the six-month period.
• As of June 30, 2024, the company had $1,384,834 in cash outside of the Trust Account and a working capital deficit of $1,992,535.
• The company is pursuing a business combination with SBC Medical Group Holdings, with a special meeting of stockholders scheduled for August 23, 2024, to approve the transaction.
• The company has until November 9, 2024, to complete a business combination, and if it fails to do so, it will be liquidated.
• The company has extended the merger agreement with SBC multiple times, with the current outside date set for September 30, 2024.
• The company has also entered into a non-redemption agreement with an investor who agreed to purchase shares in the open market and waive redemption rights, but the minimum share purchase requirement has not yet been met.

Sentiment

Score: 3

Explanation: The document presents a concerning picture with net losses, a working capital deficit, Nasdaq non-compliance, and the risk of liquidation. While the company is actively pursuing a business combination, the numerous challenges and uncertainties create a negative sentiment.

Positives

• The company is actively pursuing a business combination with SBC Medical Group Holdings.
• The company has extended the deadline to complete a business combination to November 9, 2024, providing more time to finalize the transaction.
• The company has a convertible promissory note with SBC for $2,700,000, which will convert to Class A common stock upon closing of the business combination, providing additional capital.

Negatives

• The company reported a net loss of $308,266 for the three months ended June 30, 2024, and a net loss of $600,812 for the six months ended June 30, 2024.
• The company has a working capital deficit of $1,992,535 as of June 30, 2024.
• The company has received notices from Nasdaq regarding non-compliance with listing rules.
• The company faces a mandatory liquidation if a business combination is not completed by November 9, 2024.
• The non-redemption agreement with an investor has not yet met the minimum share purchase requirement.

Risks

• The company may not be able to complete a business combination by November 9, 2024, which would result in liquidation.
• The company's working capital deficit and lack of liquidity raise substantial doubt about its ability to continue as a going concern.
• The company is subject to a 1% excise tax on stock repurchases, which could reduce available cash.
• The company is not in compliance with Nasdaq listing rules regarding publicly held shares and market value of publicly held shares.
• The business combination with SBC is subject to various conditions and may not be completed.

Future Outlook

The company intends to complete its business combination with SBC Medical Group Holdings by November 9, 2024. If the business combination is not completed by this date, the company will be liquidated.

Management Comments

• Management plans to address the uncertainty of the company's going concern status with the successful closing of the business combination.
• Management believes that the mandatory liquidation, along with the lack of liquidity, should a business combination not occur, and potential subsequent dissolution, raises substantial doubt about the company's ability to continue as a going concern.

Industry Context

The document is a quarterly report for a special purpose acquisition company (SPAC), which is a type of company that raises capital through an IPO with the goal of acquiring an existing company. The report reflects the challenges and uncertainties faced by SPACs, including the need to complete a business combination within a specified timeframe and the risk of liquidation if a deal is not completed. The report also highlights the impact of market conditions and regulatory changes on SPACs.

Comparison to Industry Standards

• The financial performance of Pono Capital Two, Inc. is typical for a SPAC in its pre-merger phase, with no operating revenue and reliance on interest income from its trust account.
• The company's operating expenses are in line with other SPACs, primarily consisting of legal, accounting, and due diligence costs.
• The company's cash position and working capital deficit are concerning, as they indicate a limited runway to complete the business combination.
• The company's non-compliance with Nasdaq listing rules is a significant issue that needs to be addressed to maintain investor confidence.
• The multiple extensions of the merger agreement with SBC are not uncommon for SPACs, but they also highlight the challenges in completing a business combination.
• The company's reliance on a convertible promissory note from the target company is a common practice for SPACs, but it also indicates a potential lack of other financing options.
• Compared to other SPACs, Pono Capital Two, Inc. is facing significant challenges in completing its business combination and maintaining its listing status, which could lead to liquidation if not resolved.

Related Party Transactions

• The company has an administrative support agreement with its Sponsor, Mehana Capital LLC, for $10,000 per month.
• The company has a convertible promissory note with SBC for $2,700,000.
• The company may receive working capital loans from its initial stockholders, officers, and directors or their affiliates.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the business combination is not completed and the company is liquidated.
• Employees of the company face uncertainty about their future employment if the company is liquidated.
• The company's creditors face the risk of not being repaid if the company is liquidated.
• The company's potential target, SBC Medical Group Holdings, faces uncertainty about the completion of the business combination.

Next Steps

• The company will hold a special meeting of stockholders on August 23, 2024, to approve the business combination with SBC Medical Group Holdings.
• The company needs to regain compliance with Nasdaq listing rules by November 4, 2024.
• The company needs to complete the business combination by November 9, 2024, to avoid liquidation.
• The company needs to finalize the non-redemption agreement with the investor by September 16, 2024.

Key Dates

Keywords

business combination, SPAC, merger, SBC Medical Group Holdings, special purpose acquisition company, redemption, liquidation, Nasdaq, excise tax, working capital, promissory note